Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy

Vaccine

Volumn 32, Issue 26, 2014, Pages 3133-3138

  Gessner, Bradford D ^a   Feikin, Daniel R ^b,c  

^a Agence de Medecine Preventive   (France)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Cholera; Epidemiology; Haemophilus influenzae type b; Hib; Immunization; Malaria; Pneumococcus; Rotavirus; RTS,S; Streptococcus pneumoniae; Vaccine; Vaccine effectiveness; Vaccine efficacy

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; VACCINE;

CLINICAL TRIAL (TOPIC); DEVELOPING COUNTRY; EPIDEMIOLOGICAL MONITORING; HEALTH CARE POLICY; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PREVENTABLE DISEASE INCIDENCE;

CHOLERA; EPIDEMIOLOGY; HAEMOPHILUS INFLUENZAE TYPE B; HIB; IMMUNIZATION; MALARIA; PNEUMOCOCCUS; ROTAVIRUS; RTS,S; STREPTOCOCCUS PNEUMONIAE; VACCINE; VACCINE EFFECTIVENESS; VACCINE EFFICACY;

COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; HUMANS; INCIDENCE; PUBLIC HEALTH; VACCINES;

EID: 84900394930     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.019     Document Type: Review

References (24)

1. Feikin D.R., Scott A.G., Gessner B.D. Using vaccines as probes to define disease burden. Lancet 2014, (accessed on 17.02.14). 10.1016/S0140-6736(13)61682-7.
2. Gessner B.D., Brooks W.A., Neuzil K.M., Vernet G., Bright R.A., Tam J.S., et al. Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). Vaccine 2013, 31:3222-3228.
3. Mulholland E.K. Use of vaccine trials to estimate burden of disease. J Health Popul Nutr 2004, 22:257-267.
4. Gessner B.D., Sutanto A., Linehan M., Djelantik I.G., Fletcher T., Gerudug I.K., et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005, 365:43-52.
5. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365:1139-1146.
6. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
7. Feikin D.R., Laserson K.F., Ojwando J., Nyambane G., Ssempijja V., Audi A., et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine 2012, 30(Suppl. 1):A52-A60.
8. Zaman K., Anh D.D., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-congrolled trial. Lancet 2010, 376:615-623.
9. Zaman K., Roy E., Arifeen S.E., Rahman M., Raqib R., Wilson E., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008, 359:1555-1564.
10. Suzuki E., Hamamoto E., Tsuda T. On the relations between excess fraction, attributable fraction, and etiologic fraction. Am J Epidemiol 2012, 175:567-575.
11. Greenland S. Relation of probability of causation to relative risk and doubling dose: a methodologic error that has become a social problem. Am J Publ Health 1999, 89:1166-1169.
12. Gessner B.D., Baggett H.C., Muth P.T., Dunaway E., Gold B.D., Feng Z., et al. A controlled, household-randomized, open-label trial of the effect that treatment of Helicobacter pylori infection has on iron deficiency in children in rural Alaska. J Infect Dis 2006, 193:537-546.
13. Subhi R., Adamson M., Campbell H., Weber M., Smith K., Duke T., et al. The prevalence of hypoxaemia among ill children in developing countries: a systematic review. Lancet Infect Dis 2009, 9:219-227.
14. Sutter R.W., Cochi S.L., Melnick J.L. Live attenuated poliovirus vaccines. Vaccines 1999, WB Saunders Company, Philadelphia, PA. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
15. The RTS,S Clinical Trials Partnership First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. New Engl J Med 2011, 365:1863-1875.
16. The RTS,S Clinical Trials Partnership A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. New Engl J Med 2012, 367:2284-2295.
17. Sur D., Lopez A.L., Kanungo S., Paisley A., Manna B., Ali M., et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1694-1702.
18. Bhattacharya S.K., Sur D., Ali M., Kanungo S., You Y.A., Manna B., et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2013, 13:1050-1056.
19. Centers for Disease Control and Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. Morb Mortal Wkly Rep 2005, 54:893-897.
20. Moulton L.H., Chung S., Croll J., Reid R., Weatherholtz R.C., Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol 2000, 29:753-756.
21. Gessner B.D. Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa. Expert Rev Vaccines 2009, 8:91-102.
22. Hussey G.D., Lasser M.L., Reekie W.D. The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease. S Afr Med J 1995, 85:20-25.
23. Levine O.S., Schwartz B., Pierce N., Kane M. Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Pediatr Infect Dis J 1998, 17:S95-S113.
24. Shepard D.S., Walsh J.A., Kleinau E., Stansfield S., Bhalotra S. Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach. Vaccine 1995, 13:707-714.